CULLINAN THERAPEUTICS, INC. Shares Issued, Shares, Share-based Payment Arrangement, Forfeited
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CULLINAN THERAPEUTICS, INC. shares issued, shares, share-based payment arrangement, forfeited for fiscal 2025 was 501.00K shares, a 48.19% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. shares issued, shares, share-based payment arrangement, forfeited for fiscal 2024 was 967.00K shares, a 16.79% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. shares issued, shares, share-based payment arrangement, forfeited for fiscal 2023 was 828.00K shares, a 35.81% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. shares issued, shares, share-based payment arrangement, forfeited for fiscal 2022 was 1.29M shares, a 1947.62% increase from fiscal 2021.
| Period end | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 3 month | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 12 month |
|---|---|---|
| 2025-12-31 | 501.00K shares 10-K · filed 2026-03-10 | |
| 2024-12-31 | 967.00K shares 10-K · filed 2025-02-27 | |
| 2023-12-31 | 828.00K shares 10-K · filed 2024-03-14 | |
| 2022-12-31 | 1.29M shares 10-K · filed 2024-03-14 | |
| 2021-12-31 | 63.00K shares 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |